12,325 Shares in Akoya Biosciences, Inc. (NASDAQ:AKYA) Bought by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,325 shares of the company’s stock, valued at approximately $28,000.

A number of other large investors have also recently made changes to their positions in the stock. Barclays PLC raised its holdings in Akoya Biosciences by 320.9% in the third quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after purchasing an additional 30,095 shares in the last quarter. GSA Capital Partners LLP increased its holdings in Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after buying an additional 144,903 shares during the period. Finally, State Street Corp boosted its position in Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after purchasing an additional 18,361 shares in the last quarter. 79.42% of the stock is owned by hedge funds and other institutional investors.

Akoya Biosciences Price Performance

AKYA stock opened at $2.31 on Friday. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75. Akoya Biosciences, Inc. has a 1 year low of $1.88 and a 1 year high of $6.31. The firm has a market cap of $114.51 million, a P/E ratio of -1.96 and a beta of 1.23. The stock has a 50-day simple moving average of $2.60 and a 200-day simple moving average of $2.61.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AKYA. Craig Hallum lowered Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $7.00 to $5.00 in a research report on Friday, November 15th. Piper Sandler reissued an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group cut Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Akoya Biosciences has a consensus rating of “Hold” and an average target price of $5.43.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.